^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RSPO3 fusion

    i
    Other names: RSPO3, R-Spondin 3, Thrombospondin Type-1 Domain-Containing Protein 2, Thrombospondin, Type I, Domain Containing 2, Protein With TSP Type-1 Repeat, Roof Plate-Specific Spondin-3, R-Spondin-3, PWTSR, THSD2, R-Spondin 3 Homolog (Xenopus Laevis), R-Spondin 3 Homolog
    Entrez ID:
    84870
    Related biomarkers:
    Expression
    1m
    A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=89, Active, not recruiting, EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Oct 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    RSPO2 (R-Spondin 2) • RSPO3 (R-Spondin 3)
    |
    RSPO3 fusion
    |
    Keytruda (pembrolizumab) • ETC-159
    1year
    A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=89, Active, not recruiting, EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> May 2024 | Trial primary completion date: Dec 2022 --> Feb 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    RSPO2 (R-Spondin 2) • RSPO3 (R-Spondin 3)
    |
    RSPO3 fusion
    |
    Keytruda (pembrolizumab) • ETC-159